Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model

Neoplasia (United States)

Volumn 14, Issue 12, 2012, Pages 1132-1143

  Benezra, Miriam ^a   Hambardzumyan, Dolores ^b   Penate Medina, Oula ^a,d   Veach, Darren R ^a   Pillarsetty, Nagavarakishore ^a   Smith Jones, Peter ^c   Phillips, Evan ^a   Ozawa, Tatsuya ^a   Zanzonico, Pat B ^a   Longo, Valerie ^a   Holland, Eric C ^a   Larson, Steven M ^a   Bradbury, Michelle S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; FLUORINE 18; LIPOSOME; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MYC PROTEIN; NANOCARRIER; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE B; RAS PROTEIN; SKI 249380; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG SYNTHESIS; FLOW CYTOMETRY; GLIOBLASTOMA; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MOLECULAR IMAGING; MOUSE; NECROSIS; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR VOLUME; WESTERN BLOTTING;

EID: 84871561123     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.121750     Document Type: Article

References (40)

1. Morris PG and Abrey LE (2010). Novel targeted agents for platelet-derived growthfactor receptor and c-KIT in malignant gliomas. Target Oncol 5, 193-200.
2. Holland EC, Hively WP, DePinho RA, and Varmus HE (1998). A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 12, 3675-3685.
3. Holland EC, Hively WP, Gallo V, and Varmus HE (1998). Modeling mutationsin the G1 arrest pathway in human gliomas: overexpression of CDK4 but not loss of INK4a-ARF induces hyperploidy in cultured mouse astrocytes. Genes Dev 12, 3644-3649.
4. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, and Holland EC (2001).PDGF autocrine stimulation dedifferentiates cultured astrocytes and inducesoligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15, 1913-1925.
5. Fomchenko EI and Holland EC (2007). Platelet-derived growth factor-mediatedgliomagenesis and brain tumor recruitment. Neurosurg Clin N Am 18, 39-58.
6. Ahluwalia MS, de Groot J, Liu WM, and Gladson CL (2010). Targeting SRCin glioblastoma tumors and brain metastases: rationale and preclinical studies. Cancer Lett 298, 139-149.
7. Dumont RA, Hildebrandt I, Su H, Haubner R, Reischl G, Czernin JG, Mischel PS, and Weber WA (2009). Noninvasive imaging of αVβ3 function as a predictorof the antimigratory and antiproliferative effects of dasatinib. Cancer Res 69, 3173-3179.
8. Milano V, Piao Y, LaFortune T, and de Groot J (2009). Dasatinib-inducedautophagy is enhanced in combination with temozolomide in glioma. Mol CancerTher 8, 394-406.
9. Sathornsumetee S, Rich JN, and Reardon DA (2007). Diagnosis and treatmentof high-grade astrocytoma. Neurol Clin 25, 1111-1139.
10. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, et al. (2006). Phase I/II study of imatinibmesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 12, 4899-4907.
11. Chen Z, Lee FY, Bhalla KN, and Wu J (2006). Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells byBMS-354825 (dasatinib). Mol Pharmacol 69, 1527-1533.
12. Kamath AV, Wang J, Lee FY, and Marathe PH (2008). Preclinical pharmaco-kinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oralmulti-targeted kinase inhibitor against SRC and BCR-ABL. Cancer Chemother Pharmacol 61, 365-376.
13. Luo FR, Yang Z, Camuso A, Smykla R, McGlinchey K, Fager K, Flefleh C, Castaneda S, Inigo I, Kan D, et al. (2006). Dasatinib (BMS-354825) pharma-cokinetics and pharmacodynamic biomarkers in animal models predict optimal clinical exposure. Clin Cancer Res 12, 7180-7186.
14. Shah NP, Tran C, Lee FY, Chen P, Norris D, and Sawyers CL (2004). Overridingimatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401.
15. Veach DR, Namavari M, Pillarsetty N, Santos EB, Beresten-Kochetkov T, Lambek C, Punzalan BJ, Antczak C, Smith-Jones PM, Djaballah H, et al. (2007). Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib. J Med Chem 50, 5853-5857.
16. Pichot CS, Hartig SM, Xia L, Arvanitis C, Monisvais D, Lee FY, Frost JA, andCorey SJ (2009). Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells. Br J Cancer 101, 38-47.
17. Du J, Bernasconi P, Clauser KR, Mani DR, Finn SP, Beroukhim R, Burns M, Julian B, Peng XP, Hieronymus H, et al. (2009). Bead-based profiling of tyro-sine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nat Biotechnol 27, 77-83.
18. Ozawa T, Brennan CW, Wang L, Squatrito M, Sasayama T, Nakada M, Huse JT, Pedraza A, Utsuki S, Yasui Y, et al. (2010). PDGFRA gene rearrangementsare frequent genetic events in PDGFRA-amplified glioblastomas. Genes Dev 24, 2205-2218.
19. Kedar U, Phutane P, Shidhaye S, and Kadam V (2010). Advances in polymericmicelles for drug delivery and tumor targeting. Nanomedicine 6, 714-729.
20. Holland EC and Varmus HE (1998). Basic fibroblast growth factor induces cellmigration and proliferation after glia-specific gene transfer in mice. Proc Natl Acad Sci USA 95, 1218-1223.
21. Shih AH and Holland EC (2006). Platelet-derived growth factor (PDGF) andglial tumorigenesis. Cancer Lett 232, 139-147.
22. Bleau AM, Hambardzumyan D, Ozawa T, Fomchenko EI, Huse JT, Brennan CW, and Holland EC (2009). PTEN/PI3K/Akt pathway regulates the sidepopulation phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 4, 226-235.
23. Hambardzumyan D, Amankulor NM, Helmy KY, Becher OJ, and Holland EC (2009). Modeling adult gliomas using RCAS/t-va technology. Transl Oncol 2, 89-95.
24. Birdi K (1997). Handbook of Surface and Colloid Chemistry. CRC Press, BocaRaton, FL.
25. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, and Fuller GN (2000).Combined activation of Ras and Akt in neural progenitors induces glioblastomaformation in mice. Nat Genet 25, 55-57.
26. Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M, and Holland EC (2005).mTOR promotes survival and astrocytic characteristics induced by Pten/AKTsignaling in glioblastoma. Neoplasia 7, 356-368.
27. Momota H, Nerio E, and Holland EC (2005). Perifosine inhibits multiplesignaling pathways in glial progenitors and cooperates with temozolomide toarrest cell proliferation in gliomas in vivo. Cancer Res 65, 7429-7435.
28. Courtneidge SA, Kypta RM, Cooper JA, and Kazlauskas A (1991). Platelet-derived growth factor receptor sequences important for binding of src family tyrosine kinases. Cell Growth Differ 2, 483-486.
29. Gelderloos JA, Rosenkranz S, Bazenet C, and Kazlauskas A (1998). A role forSrc in signal relay by the platelet-derived growth factor α receptor. J Biol Chem 273, 5908-5915.
30. Kypta RM, Goldberg Y, Ulug ET, and Courtneidge SA (1990). Associationbetween the PDGF receptor and members of the src family of tyrosine kinases. Cell 62, 481-492.
31. Hermanson M, Funa K, Hartman M, Claesson-Welsh L, Heldin CH, Westermark B, and Nister M (1992). Platelet-derived growth factor andits receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops. Cancer Res 52, 3213-3219.
32. Nister M, Libermann TA, Betsholtz C, Pettersson M, Claesson-Welsh L, Heldin CH, Schlessinger J, and Westermark B (1988). Expression of mes-senger RNAs for platelet-derived growth factor and transforming growth factoralpha and their receptors in human malignant glioma cell lines. Cancer Res 48, 3910-3918.
33. Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, Pledger WJ, and Jove R (2007). Dasatinib inhibits migration and invasion in diversehuman sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res 67, 2800-2808.
34. Takenaka N, Mikoshiba K, Takamatsu K, Tsukada Y, Ohtani M, and Toya S(1985). Immunohistochemical detection of the gene product of Rous sarcomavirus in human brain tumors. Brain Res 337, 201-207.
35. Eustace AJ, Crown J, Clynes M, and O'Donovan N (2008). Preclinical evalua-tion of dasatinib, a potent Src kinase inhibitor, in melanoma cell lines. J TranslMed 6, 53-63.
36. Buettner R, Mesa T, Vultur A, Lee F, and Jove R (2008). Inhibition of Src familykinases with dasatinib blocks migration and invasion of human melanoma cells. Mol Cancer Res 6, 1766-1774.
37. Konecny GE, Glas R, Dering J, Manivong K, Qi J, Finn RS, Yang GR, Hong KL, Ginther C, Winterhoff B, et al. (2009). Activity of the multikinase inhibitordasatinib against ovarian cancer cells. Br J Cancer 101, 1699-1708.
38. Johnson FM, Saigal B, Talpaz M, and Donato NJ (2005). Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells. Clin Cancer Res 11, 6924-6932.
39. Torchilin VP, Lukyanov AN, Gao Z, and Papahadjopoulos-Sternberg B (2003).Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. ProcNatl Acad Sci USA 100, 6039-6044.
40. Musacchio T and Torchilin VP (2011). Recent developments in lipid-basedpharmaceutical nanocarriers. Front Biosci 16, 1388-1412.